(NASDAQ: VNDA) Vanda Pharmaceuticals's forecast annual revenue growth rate of 28.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 46.3%, and while it is forecast to beat the US market's average forecast revenue growth rate of 15.34%.
Vanda Pharmaceuticals's revenue in 2026 is $215,721,000.On average, 6 Wall Street analysts forecast VNDA's revenue for 2026 to be $16,167,722,504, with the lowest VNDA revenue forecast at $15,388,963,095, and the highest VNDA revenue forecast at $16,950,714,300. On average, 6 Wall Street analysts forecast VNDA's revenue for 2027 to be $21,986,046,874, with the lowest VNDA revenue forecast at $20,027,660,442, and the highest VNDA revenue forecast at $23,934,154,649.
In 2028, VNDA is forecast to generate $26,237,178,397 in revenue, with the lowest revenue forecast at $23,938,387,037 and the highest revenue forecast at $29,013,020,357.